Form 4: Camp4 Therapeutics Corp: Chief Medical Officer Acquires Stock Options

Yuri Maricich, Chief Medical Officer of Camp4 Therapeutics Corp, acquired stock options for 80,000 shares on April 1, 2025.

Summary

• On April 1, 2025, Yuri Maricich, the Chief Medical Officer of Camp4 Therapeutics Corp, was granted stock options.
• These options give Maricich the right to buy 80,000 shares of Camp4 Therapeutics Corp common stock at an exercise price of $3.86 per share.
• The options vest in equal monthly installments over four years, starting from the grant date.
• The options expire on March 31, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of stock options to the Chief Medical Officer aligns their interests with those of the shareholders, incentivizing them to improve the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of four years with monthly installments is also typical.
• Comparing the size of the grant (80,000 shares) to similar companies would require analyzing their executive compensation disclosures.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting their ownership if the options are exercised.
• It incentivizes the Chief Medical Officer, potentially leading to better company performance.

Key Dates

Keywords

stock options, Camp4 Therapeutics, insider trading, Form 4, Yuri Maricich, Chief Medical Officer, equity, vesting